BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 2544876)

  • 21. A high-affinity receptor for urokinase plasminogen activator on human keratinocytes: characterization and potential modulation during migration.
    McNeill H; Jensen PJ
    Cell Regul; 1990 Oct; 1(11):843-52. PubMed ID: 1965151
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.
    Skeldal S; Larsen JV; Pedersen KE; Petersen HH; Egelund R; Christensen A; Jensen JK; Gliemann J; Andreasen PA
    FEBS J; 2006 Nov; 273(22):5143-59. PubMed ID: 17042782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modulation of expression of monocyte/macrophage plasminogen activator activity and its implications for attenuation of vasculopathy.
    Lundgren CH; Sawa H; Sobel BE; Fujii S
    Circulation; 1994 Oct; 90(4):1927-34. PubMed ID: 7923681
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
    Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
    J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulated localization confers multiple functions on the protease urokinase plasminogen activator.
    Wells JM; Strickland S
    J Cell Physiol; 1997 May; 171(2):217-25. PubMed ID: 9130470
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasminogen activation in bullous pemphigoid immunohistology reveals urokinase type plasminogen activator, its receptor and plasminogen activator inhibitor type-2 in lesional epidermis.
    Schaefer BM; Jaeger C; Drepper E; Kramer MD
    Autoimmunity; 1996; 23(3):155-64. PubMed ID: 8879451
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
    Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
    J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Urokinase expression in mononuclear phagocytes: cytokine-specific modulation by interferon-gamma and tumor necrosis factor-alpha.
    Gyetko MR; Shollenberger SB; Sitrin RG
    J Leukoc Biol; 1992 Mar; 51(3):256-63. PubMed ID: 1311745
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA).
    Kobayashi H; Schmitt M; Goretzki L; Chucholowski N; Calvete J; Kramer M; Günzler WA; Jänicke F; Graeff H
    J Biol Chem; 1991 Mar; 266(8):5147-52. PubMed ID: 1900515
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of determinants involved in binding of tissue-type plasminogen activator-plasminogen activator inhibitor type 1 complexes to HepG2 cells.
    Morton PA; Owensby DA; Wun TC; Billadello JJ; Schwartz AL
    J Biol Chem; 1990 Aug; 265(24):14093-9. PubMed ID: 2167306
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interaction of single-chain urokinase-type plasminogen activator with human endothelial cells.
    Barnathan ES; Kuo A; Rosenfeld L; Karikó K; Leski M; Robbiati F; Nolli ML; Henkin J; Cines DB
    J Biol Chem; 1990 Feb; 265(5):2865-72. PubMed ID: 2154462
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Urokinase/urokinase receptor system: internalization/degradation of urokinase-serpin complexes: mechanism and regulation.
    Conese M; Blasi F
    Biol Chem Hoppe Seyler; 1995 Mar; 376(3):143-55. PubMed ID: 7612191
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modulation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2 expression by U-937 mononuclear phagocytes. Effects of 1 alpha, 25-dihydroxyvitamin D3 and phorbol ester.
    Gyetko MR; Webb AC; Sitrin RG
    J Immunol; 1988 Oct; 141(8):2693-8. PubMed ID: 3139763
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Catabolism of tissue-type plasminogen activator by the human hepatoma cell line Hep G2. Modulation by plasminogen activator inhibitor type 1.
    Morton PA; Owensby DA; Sobel BE; Schwartz AL
    J Biol Chem; 1989 May; 264(13):7228-35. PubMed ID: 2540181
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The plasminogen activator/plasmin system is up-regulated after acute necrotizing pancreatitis in human beings.
    Friess H; Duarte R; Kleeff J; Fukuda A; Tang WH; Graber H; Schilling M; Zimmermann A; Korc M; Büchler MW
    Surgery; 1998 Jul; 124(1):79-86. PubMed ID: 9663255
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity.
    Czekay RP; Kuemmel TA; Orlando RA; Farquhar MG
    Mol Biol Cell; 2001 May; 12(5):1467-79. PubMed ID: 11359936
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytokines induce urokinase-dependent adhesion of human myeloid cells. A regulatory role for plasminogen activator inhibitors.
    Waltz DA; Sailor LZ; Chapman HA
    J Clin Invest; 1993 Apr; 91(4):1541-52. PubMed ID: 8386190
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells.
    Festuccia C; Dolo V; Guerra F; Violini S; Muzi P; Pavan A; Bologna M
    Clin Exp Metastasis; 1998 Aug; 16(6):513-28. PubMed ID: 9872599
    [TBL] [Abstract][Full Text] [Related]  

  • 39. THP-1 macrophage membrane-bound plasmin activity is up-regulated by transforming growth factor-beta 1 via increased expression of urokinase and the urokinase receptor.
    Falcone DJ; McCaffrey TA; Mathew J; McAdam K; Borth W
    J Cell Physiol; 1995 Aug; 164(2):334-43. PubMed ID: 7622580
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Placenta accreta: epidemiology, molecular mechanism (hypothesis) and some clinical remarks].
    Uszyński W; Uszyński M
    Ginekol Pol; 2004 Dec; 75(12):971-8. PubMed ID: 15751221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.